Neupro approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome

For information only:

According to an article on the UCB website, Neupro will be available in the USA in the near future.

ucb.presscentre.com/News/Ne...

* Neupro (rotigotine transdermal system) is approved to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary restless legs syndrome

* Neupro is a dopamine agonist patch that provides continuous drug delivery for patients with PD and RLS

* Over 100,000 patients have been treated with Neupro® worldwide and seven pivotal trials demonstrate efficacy, safety and tolerability for PD and RLS1

* Neupro® will be available in U.S. retail pharmacies in July 2012

oldestnewest

You may also like...